News

Ocular Therapeutix Set to Shine at October Ophthalmology Events

Ocular Therapeutix Set to Shine at October Ophthalmology Events

Ocular Therapeutix Ready for October Ophthalmology Engagements

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical leader focused on transforming vision care through advanced therapies, is set to participate in a series of important meetings in Chicago this October. Their commitment to innovating solutions for retinal diseases and other eye conditions makes these events highly anticipated in the field of ophthalmology.

Insights into Presentation and Panel Schedules

This month, Ocular Therapeutix is involved in several panels and presentations across various ophthalmology conferences. Here’s what to expect:

Eyecelerator at AAO 2024

The Eyecelerator program is scheduled for October 17. The panel titled Fueling Progress: The Power of Innovation and Perseverance will feature Ocular's Executive Chair, Pravin U. Dugel, MD. This discussion is set to span from 10:00 AM to 11:00 AM, offering insights into the vital role of innovation in advancing retinal care.

Company Presentation on Transformation

Later that same day at the Eyecelerator Retina Showcase, Ocular Therapeutix will present Ocular Therapeutix: Transformation Into A Retina-focused Company. This session will be presented by Peter K. Kaiser, MD, the Chief Development Officer, scheduled for 1:24 PM to 1:31 PM, emphasizing the company's shift toward a strong focus on retinal treatments.

Participation in Innovate RETINA 2024

On October 17, Ocular Therapeutix will also participate in Innovate RETINA 2024, featuring a panel titled The Future of Retinal Therapeutics. Dr. Dugel will contribute to this forward-thinking discussion from 6:30 PM, highlighting emerging therapies and innovations that could reshape the landscape of retinal care.

Poster Presentations at AAO 2024

During the American Academy of Ophthalmology (AAO 2024) conference, running from October 18 to 21, Ocular Therapeutix will showcase a poster presentation. The presentation, Fifty-Two-Week Sustained Efficacy and Treatment Burden Reduction with OTX-TKI in the U.S. Phase 1 Trial for nAMD, led by David A. Eichenbaum, MD, FASRS, will be available on demand throughout the event, allowing attendees to delve into Ocular's latest research findings.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is dedicated to elevating vision care through its pioneering development of innovative therapies for a variety of retinal diseases and other ocular conditions. One of its primary product candidates, AXPAXLI™ (also known as OTX-TKI), employs a proprietary bioresorbable hydrogel-based formulation. Presently, AXPAXLI is undergoing Phase 3 clinical trials focusing on wet age-related macular degeneration (wet AMD), showcasing the company's commitment to advancing treatment options.

Diverse Pipeline of Innovative Therapies

Additionally, Ocular Therapeutix has leveraged its ELUTYX technology across various products, including DEXTENZA®, which has received FDA approval for treating ocular inflammation and pain after surgery. The company is also progressing with its trial for PAXTRAVA™, an intracameral implant targeting open-angle glaucoma, which has successfully completed Phase 2 clinical trials.

Stay Connected with Ocular Therapeutix

For the latest updates and information, stakeholders can follow Ocular Therapeutix through its official website, LinkedIn page, and X platform. With their ongoing efforts toward innovation in vision care, Ocular Therapeutix continues to lead in the development of effective treatments.

Frequently Asked Questions

What is Ocular Therapeutix known for?

Ocular Therapeutix specializes in innovative therapies aimed at treating retinal diseases and other ocular conditions.

When and where will Ocular Therapeutix be presenting?

The company will present at several key ophthalmology meetings in Chicago during October.

Who is presenting on behalf of Ocular Therapeutix?

Presentations will feature key executives including Pravin U. Dugel, MD and Peter K. Kaiser, MD.

What is the significance of the trials for AXPAXLI?

AXPAXLI is in Phase 3 trials, focusing on wet AMD, which represents a crucial step in advancing retinal therapy.

How can I keep up with Ocular Therapeutix news?

You can follow Ocular Therapeutix on their official website, LinkedIn, and X for updates and announcements.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NOTHING NINE's Global Ambitions: Paris Show's Impact

Updated Category News Views 0

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Continue Reading
Docusign and SAP Team Up for Seamless Business Flow

Updated Category News Views 0

Docusign Brings Its A-Game with SAP Partnership Waking up to find Docusign (NASDAQ:DOCU) teaming up with SAP is like getting a surprise deal at the Saturday market—unexpected but welcome. These two giants in their respective fields are joining forces to plant Docusign’s Intelligent Agreement Management (IAM) directly into SAP Sales Cloud and SAP SuccessFactors. If...

Continue Reading
ASICS and University of Michigan Launch Innovation Lab

Updated Category News Views 25

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Continue Reading
Zinzino Eyes European Market With New Botanical Line

Updated Category News Views 0

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 287

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 244

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Redwood and SAP Partner on Secure File Transfer

Updated Category News Views 77

Redwood Advances SAP Interiors with New File Solution October 26, '26 is now a landmark for Redwood Software. They've just rolled out their SAP Managed File Transfer solution. Got the brainpower behind Redwood and SAP operating together here, and they're offering this to enterprises aimed at optimizing their file-based workflow. If you're scratching your head just hearing...

Continue Reading
Cognizant & EBRD Unite for Tech Transformation Push

Updated Category News Views 0

An Unexpected Collaboration to Watch Sometimes partnerships come out of left field, like this one between Cognizant and the European Bank for Reconstruction and Development (EBRD). These two are teaming up to inject some serious tech smarts into the Bank's operations over the next five years. What's interesting here is the role AI and automation play in their grand...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 177

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading

Top 5 Most Recently Viewed Articles

PharmAla Biotech Supplies MDMA for Groundbreaking Clinical Trials

Updated Category News Views 75

PharmAla Biotech Advances MDMA Research with Harvard Trial PharmAla Biotech Holdings Inc has made headlines by agreeing to supply its innovative LaNeo MDMA for an upcoming clinical trial at Harvard's Maclean Hospital. Known for its commitment to neuroscience and psychiatric research, this renowned institution is set to benefit from PharmAla's advanced MDMA formulation....

Continue Reading
Socket Mobile Names New CEO Amid Strategic Shift

Updated Category News Views 11

Changing of the Guard at Socket Mobile Here's a shakeup for you: David A. Holmes just slid into the top slot as President and CEO over at Socket Mobile, Inc. (NASDAQ: SCKT), taking the wheel from Kevin Mills. Mills had been at the helm since the dawn of the millennium—March 2000, to be precise—but come June 12, he's passed the torch to Holmes. That's no small torch...

Continue Reading
Discover the Growth of Your Investment in United Airlines Stock

Updated Category News Views 166

The Growth Journey of United Airlines Holdings Investing in stocks can be a thrilling journey, especially when considering long-term gains. United Airlines Holdings (NASDAQ: UAL) has shown remarkable performance over the past 15 years, outpacing market averages by an annualized rate of 2.7%. This impressive trajectory has resulted in an average annual return of 14.28%....

Continue Reading
Employers Show Renewed Confidence in U.S. Labor Market Trends

Updated Category News Views 466

Optimism in the U.S. Labor Market: A New Wave of Hiring ZipRecruiter, a notable name in the online employment marketplace, released insights from its recent survey that showcases a revitalized optimism among U.S. employers regarding the labor market. According to the findings, a significant 76% of surveyed employers are gearing up to expand their workforce in the upcoming...

Continue Reading
Wave Life Sciences Q3 Performance Sparks Analyst Adjustments

Updated Category News Views 162

Wave Life Sciences Reports Q3 Financial Results Wave Life Sciences Ltd (NASDAQ: WVE) recently revealed its third-quarter financial results, which unfortunately fell short of analyst expectations. The company announced a loss of 32 cents per share, surpassing the consensus estimate, which predicted a loss of 30 cents per share. Additionally, Wave Life Sciences reported...

Continue Reading